Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F13A1 | P00488 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 6/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.37 |
| ▸ | PTGIS | Q16647 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6036831 | 1.00 | F13A1 (0.46) | F13A1MAPTRXFP1SCDLMNA | |
| SCHEMBL11106126 | 1.00 | F13A1 (0.46) | F13A1MAPTRXFP1SCDLMNA | |
| SCHEMBL11688948 | 1.00 | F13A1 (0.46) | F13A1MAPTRXFP1SCDLMNA | |
| SCHEMBL28837889 | 1.00 | F13A1 (0.46) | F13A1MAPTRXFP1SCDLMNA | |
| SCHEMBL11193632 | 0.86 | STAT3 (0.32) | F13A1 | |
| SCHEMBL11196622 | 0.86 | STAT3 (0.32) | F13A1 | |
| SCHEMBL11195808 | 0.86 | STAT3 (0.32) | F13A1 | |
| SCHEMBL11111988 | 0.84 | F13A1 (0.46) | F13A1MAPTRXFP1SCDLMNA | |
| SCHEMBL10689001 | 0.84 | F13A1 (0.46) | F13A1MAPTRXFP1SCDLMNA | |
| SCHEMBL18922085 | 0.83 | F13A1 (0.45) | F13A1MAPTRXFP1SCDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3594201-B1 | PROCESS FOR THE PREPARATION OF LUBIPROSTONE AND INTERMEDIATES THEREOF | CHIROGATE INT INC (TW) | 2022-02-16 | — | — | EP | disclosed |
| US-10457623-B1 | Process for the preparation of Lubiprostone and intermediates thereof | CHIROGATE INTERNATIONAL INC. (TW) | 2019-10-29 | — | — | US | disclosed |
| EP-1012137-B1 | AROMATIC C16-C20-SUBSTITUTED TETRAHYDRO PROSTAGLANDINS USEFUL AS FP AGONISTS | PROCTER & GAMBLE (US) | 2002-11-06 | — | — | EP | disclosed |
| US-4737590-A | PROSTAGLANDIN INTERMEDIATES | AMERICAN CYANAMID COMPANY (US) | 1988-04-12 | — | — | US | disclosed |
| EP-0155392-A2 | Improved processes for preparing 7-(2-hexyl-5-hydroxy-cyclopentyl)-heptanoic acid | IBI- Istituto Biochimico Italiano Giovanni Lorenzini S.p.A. (IT) | 1985-09-25 | — | — | EP | disclosed |
| US-4439365-A | TRIPHENYLMETHOXY ALKENYLMAGNESIUM HALIDES | AMERICAN CYANAMID COMPANY (US) | 1984-03-27 | — | — | US | disclosed |
| EP-0073397-A1 | Enol acylate analogs of E1 and E2 prostaglandins | MILES LABORATORIES, INC. (US) | 1983-03-09 | — | — | EP | disclosed |
| US-4363817-A | BRONCHODILATORS, GASTRIC ANTISECRETORY AGENTS AND CYTO-PROTECTIVE AGENTS | MILES LABORATORIES, INC. (US) | 1982-12-14 | — | — | US | disclosed |
| US-4343949-A | PROSTAGLANDIN REARRANGEMENTS | AMERICAN CYANAMID COMPANY (US) | 1982-08-10 | — | — | US | disclosed |
| US-4328355-A | ANTIFERTILITY AGENTS | G. D. SEARLE & CO. (US) | 1982-05-04 | — | — | US | disclosed |
| US-RE29469-E | PROSTAGLANDINS; BRONCHODILATORS, HYPOTENSIVES, ANTIULCER AGENTS | AMERICAN CYANAMID COMPANY (US) | 1977-11-08 | — | — | US | disclosed |
| US-4049805-A | 3-HYDROXY-5-ESTRANE-17-ONE | AKZONA INCORPORATED (US) | 1977-09-20 | — | — | US | disclosed |
| US-4007210-A | PROSTANOIC ACID DERIVATIVES | AMERICAN CYANAMID COMPANY (US) | 1977-02-08 | — | — | US | disclosed |
| US-3970683-A | 11,15-Dihydroxy-9-oxoprost-13-ynoic acid | G. D. SEARLE & CO. (US) | 1976-07-20 | — | — | US | disclosed |
| US-3969391-A | Preparation of prostaglandin precursors | G. D. SEARLE & CO. (US) | 1976-07-13 | — | — | US | disclosed |
| US-3969391-A | Preparation of prostaglandin precursors | G. D. SEARLE & CO. (US) | 1976-07-13 | — | — | US | disclosed |
| US-3966773-A | BRONCHODILATOR, HYPOTENSIVE, ANTIULCER | AMERICAN CYANAMID COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
| US-3965143-A | 16-Oxygenated prostanoic acid derivatives | G. D. SEARLE & CO. (US) | 1976-06-22 | — | — | US | disclosed |
| US-3950406-A | BRONCHODILATORS, HYPOTENSIVE, ANTIULCER | AMERICAN CYANAMID COMPANY (US) | 1976-04-13 | — | — | US | disclosed |
| US-3932479-A | BRONCHODILATOR, HYPOTENSIVE, ANTIULCER | AMERICAN CYANAMID COMPANY (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10457623-B1 | Process for the preparation of Lubiprostone and intermediates thereof | PTGIS, PTGIR, SQLE | F13A1 1844/4885MAPT 4832/4885RXFP1 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.